
The life science industries, including pharmaceutical, medical device, biotechnology, biological, and tobacco and tobacco-related products continue to embrace new technology to improve delivery of quality products in compliance with FDA. In addition, we’ve seen some trends toward making use of cloud services, Software-as-a-Service (SaaS) solutions, and other technical innovations that have more recently begun to be used more heavily in life science companies.
Artificial Intelligence (AI), Machine Learning (ML) and Large Language Models (LLMs), such as ChatGPT are beginning to find a presence at these companies.
While life science companies tend to lag behind other markets in using these technologies, they are catching up and we are seeing much more activity related to AI use in software applications used to develop, produce, test, and manage life science products with quality and compliance.As the pace of technological innovation and evolution becomes more intense, there is a critical need for computer system validation, 21 CFR Part 11 (Electronic Records and Electronic Signatures) compliance, and data integrity assurance to continue in environments where artificial intelligence (AI) and machine learning (ML) are becoming more prevalent.
Why Should You Attend:
Providing safe and effective FDA-regulated products is in the best interests of all those involved in their development, manufacturing, testing, and distribution. With newer technologies such as AI in the mix, it means opportunity for greater efficiency and efficacy, but also poses more challenges for companies that develop, test, and support software applications in the life science industries.
AI can hallucinate, and show bias and performance drift. The human expert must be able to critically assess the output and make the judgment calls for better decisions, quality, and compliance, and to optimize ROI.
In this webinar, you will learn just how AI, ML and LLMs, such as ChatGPT can increase efficiency and effectiveness of software development life cycle (SDLC) activities, enabling the delivery and support of computer solutions and new innovative products that will drive industry over the coming years.In particular, you’ll learn about quality metrics enhanced through AI, and how these can further streamline activities and identify and mitigate risks before they are realized.
Areas Covered in the Session :
Who Should Attend:
This webinar is intended for those involved in planning, execution and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco and tobacco-related products (e-liquids, e-cigarettes, pouch tobacco, cigars, etc.).
Functions that are applicable include research and development, manufacturing, Quality Control testing, distribution, clinical trial management, sample labeling, adverse events management, and post-marketing surveillance. Whether involved in software development, implementation, testing, validation, maintenance or use of AI-enabled solutions, you will find a wealth of knowledge to enhance your ability to use these technologies with maximum effectiveness.
Those using these systems, in particular, must understand their role as the human guardrail of AI, critically assessing the outcomes, making intelligent judgment calls, and ensuring better decisions. It’s not just about using these AI solutions, it’s about using them effectively and by critically thinking about your role and accountability to ensure you optimize quality, compliance, and ROI.
Examples of who will benefit from this webinar include:
This webinar will also benefit any vendors and consultants working in the life sciences industry who are involved in computer system implementation, validation and compliance. It will also help those in software development companies who support the life science industries.

| Carolyn Troiano has more than 45 years of experience in computer system validation in the pharmaceutical, medical device, biotechnology, tobacco, and other FDA-regulated industries. She is currently an independent consultant, advising companies on FDA compliance, Computer System Validation (CSV), and large-scale IT system implementation projects.Carolyn participated in the FDA/Industry Partnership to develop 21 CFR Part 11, the FDA’s Guidance for Electronic Records and Electronic Signatures. During her career she has provided training, including CSV, 21 CFR Part 11, Data Integrity, and many other related compliance topics of interest to the life science industries. |